... Proceeds Include Strategic Funding of Operations Outside the US I... Locations Other Than Switzerland ...BETHESDA Md. Nov. 6 /- NorthwestBiotherapeut...Under the Notes SDS and the Private Investors have loaned the Company...

BETHESDA, Md., Nov. 6 /PRNewswire-FirstCall/ -- Northwest
Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBS and NWBT), today
announced that it has obtained US$1.65 million in funding pursuant to Loan
Agreements and Promissory Notes (the "Notes") with SDS Capital Group SPC,
Ltd ("SDS") and a group of private investors (the "Private Investors"). A
significant portion of the proceeds will provide strategic funding for
expansion of NWBT's programs and capacity outside the United States, in
locations other than Switzerland.

Under the Notes, SDS and the Private Investors have loaned the Company
US$1.65 million. The Notes are unsecured obligations of the Company and
accrue interest at the rate of 12% per year. The maturity date of the notes
will be April 21, 2009. The Notes carry 50% warrant coverage (i.e., the
aggregate exercise price of the Warrants will be equal to fifty percent of
the financing). The Warrants will be exercisable for common stock of the
company at a price of US$0.41, per share (the "Warrants"). The Warrants are
exercisable immediately, and will expire 5 years from the date of issuance.
The Notes may be prepaid at the discretion of the Company at any time prior
to maturity, without any prepayment penalty; however, prepayment will not
affect the Warrants.

The Company granted SDS and the Private Investors piggyback
registration rights for any shares of the Company's common stock issued
under the Notes. The Notes also contain customary representations,
warranties and covenants. SDS will receive certain rights relating to
subsequent financings, subject to the Company's right to pre-pay SDS and
avoid the rights being triggered. Under these rights, the Company will
notify SDS of any subsequent financings that take place while this SDS Note
is outstanding, and SDS will have an opportunity to participate. However,
SDS' right to notice and participation are subject to the Company's right
to pay off SDS' Note prior to the applicability of these rights, and to
avoid the rights being triggered.

The Company will use the proceeds from these Notes for operating
expenses and other obligations of the Company, and a significant portion of
the proceeds will be used to provide strategic funding of the Company's
business plan and strategy for countries other than the US and Switzerland.
The uses of proceeds will include establishment of GMP manufacturing
facilities, regulatory filings, clinical trial expenses, product
manufacturing and sales, and other related expenses.

"We are very pleased to have completed another interim financing
despite severely adverse general market conditions," said NWBT's Chief
Executive Officer Alton Boynton. "We are especially pleased to have
received a second round of investment from SDS Capital, a well known
institutional investor with a highly successful track record of investments
in the healthcare sector."

The US$1.65 million loan received by the Company will be sufficient to
fund its cash needs into December, 2008. The Company remains in an advanced
stage of negotiations with several different providers for additional
near-term funding and longer term funding, which it hopes to complete by
the end of the year.

The Company will need to raise additional capital to fund its clinical
trials and other operating activities and to repay indebtedness in due
course. Shareholders should be aware that if the Company's capital raising
efforts are unsuccessful, this will have a material adverse effect on the
Company's financial position and operations.

About NWBT

Northwest Biotherapeutics, Inc. is a biotechnology company focused on
developing immunotherapy products that treat cancers more effectively than
current treatments, with limited toxicity, on a cost-effective basis. The
Company has two broad platform technologies: dendritic cell-based vaccines,
and therapeutic antibodies. The Company is currently conducting a large
clinical trial in Glioblastoma multiforme, which is designed and powered to
serve as a pivotal trial. The Company has also received clearance from the
FDA for a large Phase III trial in prostate cancer, and clearance from the
FDA for Phase I trials in five other cancers. The Company has started, and
is currently enrolling patients in, a Phase I/II trial with DCVax(R) for
recurrent ovarian cancer. The Company also has a second technology
platform, involving monoclonal antibodies to CXCR4, which is at the late
pre-clinical development stage.

Statements made in this news release that are not historical facts,
including statements concerning the Company's plans to move its programs
forward, either in the U.S. or outside the U.S., statements regarding the
Company's clinical trials and other business development activities, and
statements regarding its fundraising activities, are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Words such as "expects," "believes," "intends," and similar
expressions are intended to identify forward-looking statements. Actual
results may differ materially from those projected in any forward-looking
statement. Specifically, there are a number of important factors that could
cause actual results to differ materially from those anticipated, such as
risks and uncertainties regarding the Company's ability to secure
additional financing or raise additional capital, risks related to the
Company's ability to enroll patients in its clinical trials and complete
the trials on a timely basis, the uncertainty of the clinical trials
process, uncertainties about the Company's ability to deliver its products
to patients and charge patients, uncertainties about the timely performance
of third parties, and whether the Company's products will demonstrate
safety and efficacy. Additional information on these and other factors,
which could affect the Company's results, is included in its Securities and
Exchange Commission ("SEC") filings, including in the Risk Factors section
of the Company's Annual Report on Form 10-K for the year ended December 31,
2007 and in its recently filed Form S-1. Finally, there may be other
factors not mentioned above or included in the Company's SEC filings or
recently filed Form S-1 that may cause actual results to differ materially
from those projected in any forward-looking statement. You should not place
undue reliance on any forward-looking statements. The Company assumes no
obligation to update any forward-looking statements as a result of new
information, future events or developments, except as required by
securities laws.

(Date:12/8/2016)... , Dec. 8, 2016 Anaconda BioMed S.L., a ... of the next generation neuro-thrombectomy system for the treatment ... Tudor G. Jovin, MD to join its Scientific Advisory ... a strategic network of scientific and clinical experts to ... of the ANCD BRAIN ® to its clinical ...

(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...